Other strategies under evaluation for KRAS mutant NSCLC include the inhibition of downstream signaling pathways with MEK inhibitors (NCT04967079, NCT03170206), either as monotherapy or combined with other molecules (NCT03170206, NCT04735068). The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.